6 / 42
La frecuencia de mutaciones somáticas en cáncer se
correlaciona con la respuesta a Inmunoterapia
Yarchoan, M et al. Nat Rev Cancer 2017
NSCLC
(never
smokers)
0.1
0
10
20
30
40
50
1
10
100
Prostate
Colon (MMR-P)
Ewing sarcoma
Gastric
Bladder
SCLC
Ovarian
Breast (triple negative)
Oesophageal (squamous)
RCC
NSCLC (smokers)
MCC (MCPyV-negative)
Melanoma
Colon (MMR-D)
ORR with PD1–PDL1 inhibition (%)
Somatic mutation frequency (per Mb)
provided indisputable
can recognize and de
destroy established ca
checkpoint inhibitors,
displayed byMHCs on
any class of tumour a
T cells; however, it i
serve as the most im
tain cancers where im
shown clinical efficac
demonstrated to be T
mice treated with im
administration of pept
antigens into mice c
to immune checkpoi
PD1-expressing neoa
identified in the perip
noma, correlating with
of PD1 inhibitors in th
Tumour somatic mut
REV I EWS